News Releases

Leading New Gene-based Therapies

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer


Dr. Dybul’s Deep and Prestigious Scientific Research Expertise Helps to Affirm Enochian BioScience’s Scientific Approach   LOS ANGELES, July 20, 2021 (NASDAQ: ENOB) – Enochian BioSciences, Inc., a company focused on gene-modified cellular and immune therapies in infectious diseases and cancer, today announced that Honorable Mark Dybul, M.D. has been named as Chief Executive Officer

Read more

Enochian BioSciences Names The Hon. Dr. Mark Dybul as Chief Executive Officer

July 20, 2021


Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential Cure for Hepatitis B Virus Infection

July 12, 2021


Enochian BioSciences Announces Scientific Presentation of Elimination of HBV in Mice with No Evident Toxicity

June 30, 2021


Enochian BioSciences Announces Acquisition of Exclusive License for Potential Pan-Coronavirus and Pan-Influenza Inhaled Treatment and Prevention Technology

June 21, 2021


Enochian BioSciences Announces $29 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

June 14, 2021


Enochian BioSciences Announces FDA Acceptance of Pre-IND Request For Potential HIV Cure

June 14, 2021


Enochian BioSciences announces Scientific Presentation of a Person with HIV Exhibiting Controlled Blood Levels of Virus for 255 Days Following Treatment with a Novel Cellular Therapy

May 12, 2021


Seraph Research Institute and Enochian BioSciences Publish a Case Report of Complete Remission of Recurrent Glioblastoma with Innovative Therapy

March 24, 2021


Enochian BioSciences to Present to Investors at the H.C. Wainwright Global Life Sciences Conference

February 22, 2021


Enochian BioSciences to Present to Investors at 22nd Annual H.C. Wainwright Global Investment Conference

September 10, 2020


Distinguished Scientific Leaders to Join Enochian BioSciences Hepatitis B Scientific Advisory Board

July 27, 2020


Enochian BioSciences Announces Its Successful Completion of FDA INTERACT Meeting for a Potential Cure for HIV

June 8, 2020